Small Lymphocytic Lymphoma

The FDA granted accelerated approval to lisocabtagene maraleucel for treatment of certain patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

The FDA granted accelerated approval to pirtobrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.

The FDA announced several regulatory actions.

A phase 1/phase 2 trial of lisocabtagene maraleucel for adults with advanced chronic lymphocytic leukemia or small lymphocytic lymphoma met its primary endpoint, according to the agent’s manufacturer.

The FDA approved zanubrutinib for treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma.

An FDA advisory panel voted 8-4 that duvelisib did not have a favorable benefit-risk profile for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who received at least two prior therapies.

The FDA issued a warning about a potentially increased risk for death or serious adverse effects with duvelisib, an approved blood cancer therapy.

SALT LAKE CITY — Zanubrutinib improved outcomes compared with bendamustine/rituximab among adults with treatment-naive deletion 17p-negative chronic lymphocytic leukemia or small lymphocytic lymphoma, according to phase 3 study results.

Zanubrutinib prolonged PFS compared with bendamustine plus rituximab among patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma who did not harbor deletion 17p.

Fixed-duration first-line treatment with ibrutinib plus venetoclax induced deep, durable responses among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, according to results of the phase 2 CAPTIVATE study.